Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 9:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Terminated No phase listed Observational

Frovatriptan and Menstrual Migraine

NCT01114711
Conditions
Frovatriptan, Menstrual Migraine
Interventions
Not listed
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Belmont, Massachusetts
Conditions
Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
6 Years to 12 Years
Enrollment
293 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Migraine
Interventions
Ubrogepant, Placebo-Matching Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,059 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
124
States / cities
Huntsville, Alabama • Saraland, Alabama • Phoenix, Arizona + 102 more
Completed Not applicable Interventional Results available

Evaluation of a Novel Device for Treatment of Migraine Headache

NCT03361423
Conditions
Migraine Without Aura, Migraine With Aura
Interventions
Nerivio Migra-1 active device, Nerivio Migra-1 Sham device
Device
Lead sponsor
Theranica
Industry
Eligibility
18 Years to 75 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
Hartford, Connecticut • Springfield, Missouri • St Louis, Missouri + 4 more
Conditions
Menstrual Migraine (MM) Headaches
Interventions
Frovatriptan, Usual Care
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
21
States / cities
Stratford, Connecticut • Clearwater, Florida • Jacksonville, Florida + 18 more
Conditions
Migraine
Interventions
Saline, lidocaine/bupivacaine
Drug · Combination Product
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers

Transnasal Therapy for Acute Migraine Attack

NCT04129567
Conditions
Migraine Disorders
Interventions
Humidified oxygen, Dry oxygen, Humidified air, Dry air
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Acute Migraine
Interventions
Zavegepant (BHV-3500)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
67
States / cities
Huntsville, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more
Conditions
Migraine, Acute Treatment of Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bridgewater, New Jersey
Conditions
Migraine, Migraine With or Without Aura, Migraine, Acute, Migraine Headache
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 3 Interventional Results available

Maximizing Outcomes in Treating Acute Migraine

NCT03896009
Conditions
Migraine
Interventions
AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,594 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 80 more
Conditions
Migraine, Cannabis, THC
Interventions
THC ~2.5%, THC ~5%, THC ~10%, Sham Cannabis
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
La Jolla, California
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Conditions
Acute Treatment of Migraine
Interventions
Rimegepant (PF-07899801)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
115
States / cities
Scottsdale, Arizona • Tempe, Arizona • Anaheim, California + 77 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ketamine for Acute Migraine in the Emergency Department

NCT02697071
Conditions
Headache
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Roanoke, Virginia
Conditions
Migraine
Interventions
Zavegepant
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Migraine With or Without Aura
Interventions
Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more
Conditions
Migraine, Migraine With Aura, Migraine Without Aura
Interventions
Dihydroergotamine, Placebo
Drug
Lead sponsor
Satsuma Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,591 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
127
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 106 more
Conditions
Migraine Disorders
Interventions
sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
49
States / cities
Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 43 more
Conditions
Migraine
Interventions
Elismetrep, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
72
States / cities
Glendale, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 64 more
Conditions
Migraine
Interventions
Diclofenac Potassium for Oral Solution
Drug
Lead sponsor
Depomed
Industry
Eligibility
12 Years to 17 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Tampa, Florida • Amherst, New York
Conditions
Migraine
Interventions
Elismetrep (K-304) 2 mg, Elismetrep (K-304) 5 mg, Elismetrep (K-304) 10 mg, Elismetrep (K-304) 20 mg, Placebo
Drug
Lead sponsor
Kallyope Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Conditions
Migraine
Interventions
No intervention: We are testing for the presence of allodynia
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Episodic Migraine
Interventions
Sham Treatment Location, Verum Treatment Location
Device
Lead sponsor
Theranova, L.L.C.
Industry
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona